Quick answer: Semaglutide side effects are usually most noticeable when treatment begins or after the dose increases. Nausea, diarrhea, vomiting, constipation, abdominal discomfort, reflux, headache and fatigue are among the most commonly reported effects. Many are mild to moderate and improve as the body adjusts.[1,2]

However, severe or persistent abdominal pain, repeated vomiting, dehydration, difficulty breathing, facial swelling, yellowing of the skin or eyes, sudden vision changes or severe low-blood-sugar symptoms require prompt medical attention.

There is no exact week when a particular side effect must begin or disappear. Symptoms are influenced more by dose, escalation, formulation, meal size, hydration, other medications and individual susceptibility than by the calendar alone.

Side effects at a glance

Symptom	Often manageable	Contact a clinician promptly or seek urgent care
Nausea	Mild, able to drink and eat small meals	Persistent, worsening or preventing hydration
Vomiting	Isolated episode with continued fluid intake	Repeated vomiting, faintness or little urination
Constipation	Mild and passing gas normally	Severe pain, swelling, vomiting or inability to pass gas
Diarrhea	Mild and temporary	Bloody stool, severe weakness or dehydration
Abdominal pain	Mild, brief discomfort	Severe, persistent or radiating to the back
Reflux or burping	Mild and meal-related	Chest pain, vomiting blood or black stool
Low appetite	Able to maintain nutrition and hydration	Unable to eat, severe weakness or rapid nutritional decline
Injection reaction	Small, mild and improving	Spreading redness, pus, fever or facial/throat swelling
Vision changes	None expected	Sudden or significant change, especially with diabetes
Low blood sugar	Mild symptoms corrected promptly	Confusion, seizure, unconsciousness or inability to swallow

This table is not a substitute for individual medical assessment.

Why semaglutide causes digestive side effects

Semaglutide activates glucagon-like peptide-1, or GLP-1, receptors. It reduces appetite, influences glucose-dependent insulin release and delays gastric emptying.

These effects can help with weight management and blood-sugar control, but they can also produce:

• Earlier fullness
• Nausea
• Vomiting
• Constipation
• Diarrhea
• Abdominal discomfort
• Bloating
• Burping
• Indigestion or reflux

Symptoms commonly occur during dose escalation. Starting low and increasing gradually is intended to improve tolerability.[1]

Severe symptoms are not evidence that semaglutide is “working better.” The goal is meaningful benefit with acceptable tolerability.

Weeks 1–4: Starting-dose side effects

For injectable Wegovy, treatment ordinarily begins at 0.25 mg once weekly for four weeks.[1] Other semaglutide products have different instructions.

During the first month, possible effects include:

• Mild nausea
• Earlier fullness
• Reduced appetite
• Burping
• Bloating
• Constipation
• Loose stool
• Fatigue
• Headache
• No side effects

Not having symptoms does not mean the medication is ineffective.

What may help

• Eat smaller portions.
• Eat slowly.
• Stop when comfortably full.
• Avoid lying down immediately after eating.
• Drink fluids regularly.
• Limit unusually heavy or high-fat meals when nauseated.
• Increase fiber gradually rather than suddenly.
• Maintain gentle activity as tolerated.

Do not take an additional dose because you felt no side effects.

Weeks 5–8: Symptoms may return after escalation

The labeled Wegovy injection schedule ordinarily increases to 0.5 mg once weekly during weeks 5–8.[1]

Some patients who tolerated the first month develop temporary symptoms after increasing the dose. Others continue without difficulty.

Possible effects include:

• Nausea after meals
• Reduced meal capacity
• Constipation
• Diarrhea
• Reflux
• Fatigue
• Abdominal discomfort

The timing varies. Symptoms may begin soon after an injection or emerge later in the week.

When to contact the prescriber

Contact the prescribing clinician if:

• Symptoms interfere with work or routine activity.
• You cannot eat enough to maintain nutrition.
• Constipation persists despite reasonable measures.
• Vomiting recurs.
• You are unsure whether to take the next dose.
• You want to delay escalation.

The current Wegovy label states that when a dose is not tolerated during escalation, delaying the next increase for four weeks may be considered.[1] That decision belongs to the prescriber.

Weeks 9–12: Higher-dose gastrointestinal effects

The traditional injectable Wegovy schedule progresses to 1 mg once weekly during weeks 9–12.[1]

Dose-related symptoms can recur even if the earlier steps were tolerated.

Monitor for:

• Increasing nausea
• Reduced fluid intake
• Constipation
• Repeated diarrhea
• Dizziness when standing
• Reduced urination
• Abdominal pain

Dizziness, dark urine, dry mouth or little urination can suggest dehydration.

Semaglutide itself is not directly toxic to the kidneys in the usual sense, but vomiting and diarrhea can cause volume depletion and acute kidney injury. The current label advises monitoring kidney function when adverse effects could cause dehydration.[1]

Weeks 13–16: Deciding whether escalation remains tolerable

The labeled Wegovy injection schedule ordinarily reaches 1.7 mg once weekly during weeks 13–16.[1]

At this stage, the prescriber should consider both benefit and tolerability. A patient should not increase simply because a calendar says it is time.

Important questions include:

• Can you drink adequately?
• Are you eating enough protein and nutrients?
• Is constipation manageable?
• Are symptoms improving between doses?
• Are you experiencing significant weakness?
• Are you using insulin or a sulfonylurea?
• Is weight loss occurring at a medically reasonable rate?

A slower escalation can be safer than progressing through unresolved adverse effects.

Week 17 and beyond: Maintenance-dose effects

For adult weight reduction, the current Wegovy injection label lists 1.7 or 2.4 mg once weekly as maintenance doses, with 2.4 mg recommended.[1]

Selected adults who tolerate 2.4 mg for at least four weeks and require additional weight reduction may be considered for Wegovy HD 7.2 mg once weekly under prescriber supervision.[1]

A higher labeled dose is not automatically better. Gastrointestinal tolerability, treatment response and the complete medical situation must be considered.

New or worsening symptoms after months of stability should not always be attributed to semaglutide. Gallstones, pancreatitis, infection, pregnancy, bowel disorders and other conditions can occur independently.

Nausea: What may help

Nausea is among the most common semaglutide adverse effects.

Possible supportive measures include:

• Smaller, more frequent meals
• Eating slowly
• Stopping before feeling overly full
• Avoiding very greasy meals when symptomatic
• Drinking fluids between meals
• Choosing bland foods temporarily when needed
• Avoiding alcohol when it worsens symptoms
• Remaining upright after eating

Contact the prescriber before adding medication for persistent nausea. Repeatedly masking severe symptoms without evaluating their cause can delay recognition of dehydration, gallbladder disease or pancreatitis.

Vomiting: When it becomes concerning

A single episode that resolves is different from repeated vomiting.

Contact a clinician promptly when vomiting:

• Happens repeatedly
• Prevents fluid intake
• Continues into the next day
• Occurs with significant abdominal pain
• Causes dizziness or faintness
• Is associated with little urination
• Contains blood or dark material resembling coffee grounds

Semaglutide remains in the body for a prolonged period, so significant adverse effects may not disappear immediately after withholding one dose.

Constipation: Practical management and warning signs

Constipation can result from reduced food intake, delayed gastrointestinal movement, inadequate fluid, low fiber or reduced activity.

Depending on your medical situation, a clinician may recommend:

• Adequate hydration
• Gradual dietary fiber
• Fruits, vegetables or whole grains as tolerated
• Regular walking
• A fiber supplement
• An osmotic laxative such as polyethylene glycol

Do not suddenly load large amounts of fiber when severely bloated or inadequately hydrated.

Seek prompt care for constipation with:

• Severe or worsening abdominal pain
• Marked abdominal swelling
• Repeated vomiting
• Fever
• Blood in the stool
• Inability to pass stool or gas

These symptoms can suggest a condition requiring assessment rather than routine home treatment.

Diarrhea: Protecting against dehydration

Mild diarrhea may improve as the body adjusts.

Focus on:

• Replacing fluids
• Monitoring urination
• Avoiding alcohol
• Temporarily limiting foods that worsen symptoms
• Reviewing other medications that can cause diarrhea

Contact a clinician for:

• Persistent diarrhea
• Bloody or black stool
• Fever
• Severe abdominal pain
• Dizziness
• Weakness
• Reduced urination
• Signs of low blood sugar

People with kidney disease, older adults and those taking diuretics may become dehydrated more easily.

Reflux, burping and bloating

Because semaglutide delays gastric emptying, larger meals may remain uncomfortable for longer.

Strategies may include:

• Smaller meals
• Avoiding overeating
• Remaining upright after eating
• Limiting personal trigger foods
• Avoiding late-night meals
• Discussing appropriate antacid treatment with a clinician

Chest pressure or pain should not automatically be labeled reflux. Seek emergency evaluation for possible cardiac symptoms, particularly when pain occurs with exertion, shortness of breath, sweating, weakness or radiation to the arm, jaw or back.

Pancreatitis warning

Acute pancreatitis has been observed with GLP-1 receptor agonists, including Wegovy.[1]

Possible symptoms include:

• Severe, persistent upper-abdominal pain
• Pain radiating to the back
• Nausea or vomiting
• Significant abdominal tenderness

Stop using the medication and obtain immediate medical evaluation when pancreatitis is suspected, following emergency or prescriber guidance. Do not attempt to diagnose pancreatitis solely by symptom location or an online checklist.

Gallbladder disease

Semaglutide treatment and rapid weight loss may be associated with gallstones or gallbladder inflammation.

Concerning symptoms include:

• Persistent right-upper-abdominal pain
• Pain after eating
• Pain extending to the right shoulder or back
• Fever
• Repeated vomiting
• Yellow skin or eyes
• Dark urine or pale stool

These symptoms warrant medical evaluation. Gallbladder disease may require laboratory testing and imaging.

Severe gastroparesis and prolonged fullness

Semaglutide delays gastric emptying. The current Wegovy label states that it is not recommended for patients with severe gastroparesis.[1]

Contact a clinician if you develop:

• Persistent vomiting of undigested food
• Severe or prolonged fullness
• Inability to meet nutrition or hydration needs
• Significant abdominal swelling
• Progressive weight loss with weakness
• Symptoms that do not improve between doses

These findings should not be dismissed as ordinary appetite suppression.

Hypoglycemia risk

Semaglutide alone has a lower risk of causing hypoglycemia than insulin or sulfonylureas. The risk increases when it is combined with:

• Insulin
• Sulfonylureas such as glipizide, glyburide or glimepiride
• Other medications that increase insulin secretion

Symptoms may include:

• Shaking
• Sweating
• Rapid heartbeat
• Hunger
• Dizziness
• Confusion
• Weakness
• Blurred vision

Patients using these combinations may need closer glucose monitoring and adjustment of the other diabetes medication by the prescriber.[1]

Severe confusion, seizure, unconsciousness or inability to swallow is an emergency.

Diabetic retinopathy and vision changes

Rapid improvement in blood glucose can temporarily worsen diabetic retinopathy in susceptible patients. The current label advises monitoring patients with a history of diabetic retinopathy.[1]

Contact an eye professional or medical clinician promptly for:

• Sudden vision loss
• New floaters
• Flashes of light
• A curtain-like shadow
• Significant new blurred vision

Do not assume every visual symptom is a routine medication effect.

Allergic reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.[1]

Seek emergency care for:

• Difficulty breathing
• Throat tightness
• Facial, tongue or throat swelling
• Widespread hives
• Faintness or collapse

A small injection-site reaction is different from a systemic allergic reaction, but spreading redness, fever, drainage or worsening pain should also be evaluated.

Surgery, procedures and anesthesia

Semaglutide delays gastric emptying. Rare pulmonary-aspiration events have been reported in patients receiving GLP-1 medications during general anesthesia or deep sedation despite following fasting instructions.[1]

Tell the following clinicians that you use semaglutide:

• Surgeon
• Anesthesiologist
• Gastroenterologist
• Dentist providing deep sedation
• Procedure team

Do not decide independently whether to stop or continue semaglutide before a procedure. The plan depends on the procedure, formulation, symptoms, dose-escalation phase and individual aspiration risk.

Pregnancy and semaglutide

Weight loss provides no benefit during pregnancy and may cause harm.

For weight reduction or cardiovascular risk reduction, current Wegovy labeling advises discontinuation when pregnancy is recognized and discontinuation at least two months before a planned pregnancy because semaglutide has a long half-life.[1]

Discuss pregnancy plans, contraception and breastfeeding with the prescriber.

Mental-health symptoms and the 2026 label change

Older articles may state that Wegovy carries a warning for suicidal behavior or thoughts. That warning was removed from the U.S. Wegovy prescribing information in January 2026.[1]

This does not mean new depression, suicidal thoughts or major behavioral changes should be ignored. Anyone with immediate risk of self-harm should call emergency services or, in the United States, call or text 988.

Compounded semaglutide side-effect concerns

Compounded semaglutide is not FDA-approved and may be supplied in varying concentrations.

The FDA has reported dosing mistakes in which patients took five to 20 times the intended amount after confusing milligrams, milliliters and syringe units. Reported problems included severe nausea, vomiting, abdominal pain, fainting, dehydration, pancreatitis and gallstones.[3]

If you use a compounded product, confirm:

• The precise concentration in mg/mL
• The prescribed dose in milligrams
• The volume in milliliters
• The correct syringe marking
• The pharmacy
• Storage instructions

Do not rely on a generic online conversion table.

When should semaglutide be stopped?

Do not stop a chronic prescription casually, but seek immediate medical guidance when serious adverse effects are suspected.

Urgent discontinuation and evaluation may be necessary for suspected:

• Pancreatitis
• Serious allergic reaction
• Severe dehydration
• Pregnancy when used for weight reduction
• Another serious complication identified by a clinician

For routine nausea, constipation or mild side effects, contact the prescriber before making changes. The clinician may delay escalation, reduce the dose, address a contributing condition or discontinue treatment.

Frequently asked questions

What week are semaglutide side effects the worst?

There is no universal worst week. Symptoms are often most noticeable after starting or increasing the dose.

Do side effects mean semaglutide is working?

No. People can lose weight without significant side effects, and severe symptoms do not predict superior results.

How long does nausea last?

Mild nausea may improve over days or weeks, but the pattern varies and may recur after dose escalation. Persistent or severe nausea warrants review.

Should I take my next dose if I am still vomiting?

Contact the prescriber before taking another dose. Repeated vomiting can cause dehydration and may indicate a complication.

Can I lower the dose myself?

No. Discuss dose changes with the prescriber. The safest plan depends on the product, indication, duration, response and severity of symptoms.

Is constipation dangerous?

Mild constipation is common. Severe pain, vomiting, abdominal swelling or inability to pass gas requires prompt assessment.

Can I use anti-nausea or constipation medication?

Sometimes, but treatment should be appropriate for your health history and should not conceal a serious cause. Ask a clinician or pharmacist.

Bottom line

Semaglutide side effects are usually most noticeable during initiation and dose escalation. Mild nausea, constipation, diarrhea, reflux, fatigue or abdominal discomfort may improve as the body adjusts.

Contact a clinician when symptoms are persistent, worsening or interfering with hydration and nutrition. Seek urgent care for:

• Severe or persistent abdominal pain
• Repeated vomiting
• Significant dehydration
• Facial or throat swelling
• Difficulty breathing
• Yellow skin or eyes
• Severe low blood sugar
• Sudden vision changes
• Severe constipation with vomiting or inability to pass gas

Do not increase the dose through unresolved symptoms. Effective semaglutide treatment should balance benefit, nutrition, hydration and tolerability.

---

Medical review: Mark Aquino, MSN, APRN, FNP-C, board-certified family nurse practitioner.

Medical disclaimer: This article provides general educational information and is not an individualized diagnosis or treatment plan. Semaglutide requires evaluation, prescribing and monitoring by a qualified healthcare professional. Seek prompt medical care for severe or concerning symptoms.

References

1. Novo Nordisk Inc. Wegovy (semaglutide) injection and tablets: US prescribing information. Revised June 2026.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
3. US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Published July 26, 2024.
4. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated 2026.